The designer proline-rich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models

International Journal of Antimicrobial Agents

Volumn 35, Issue 4, 2010, Pages 357-361

  Szabo, Dora ^a   Ostorhazi, Eszter ^b   Binas, Annegret ^c   Rozgonyi, Ferenc ^a,b   Kocsis, Bela ^a   Cassone, Marco ^d   Wade, John D ^e   Nolte, Oliver ^c   Otvos Jr , Laszlo ^f  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b Central Microbiology Laboratory   (Hungary)

^c AiCuris GmbH   (Germany)

^d TEMPLE UNIVERSITY   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f Temple University   (United States)

Author keywords

Bacterial counts; Extended spectrum lactamase; Inhibition of protein folding; Kidney elimination; Peptide antibiotics; Sepsis model; Survival rate

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; CISPLATIN; HYDROXY 1 AMINO CYCLOHEXANE CARBOXYLIC ACID ARGINYLPROLYLASPARAGINYLLYSYLPROLYLARGININYLPROLYLTYROSYLLEUCYLPROLYLARGINYLPROLYLPROLYLARGINYLPROLYLVALYLARGININE 2,4 DIAMINO BUTYRIC ACID AMIDE; IMIPENEM; MEROPENEM; POLYPEPTIDE ANTIBIOTIC AGENT; PROLINE; PROTEIN DNAK; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI 5770; ESCHERICHIA COLI INFECTION; FEMALE; GROWTH INHIBITION; IMMUNOSTIMULATION; IN VIVO STUDY; KIDNEY CLEARANCE; KLEBSIELLA PNEUMONIAE; LETHAL DOSE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA; SURVIVAL RATE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; INJECTIONS, INTRAPERITONEAL; KIDNEY; KLEBSIELLA PNEUMONIAE; MICE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PEPTIDES; SALMONELLA TYPHIMURIUM; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 76749084744     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.10.015     Document Type: Article

References (27)

1. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415 (2002) 389-395
2. Ge Y., MacDonald D.L., Holroyd K.J., Thornsberry C., Wexler H., and Zasloff M. In vitro properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother 43 (1999) 782-788
3. Bush K., Macielag M., and Weidner-Wells M. Taking inventory: antibacterial agents currently at or beyond Phase I. Curr Opin Microbiol 7 (2004) 466-476
4. Marr A.K., Gooderham W.J., and Hancock R.E.W. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 6 (2006) 468-472
5. Dartois V., Sanchez-Quesada J., Cabezas E., Chi E., Dubbelde C., Dunn C., et al. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob Agents Chemother 49 (2005) 3302-3310
6. Deslouches B., Islam K., Craigo J.K., Paranjape S.M., Montelaro R.C., and Mietzner T.A. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob Agents Chemother 49 (2005) 3208-3216
7. Otvos Jr. L., Wade J.D., Lin F., Condie B.A., Hanrieder J., and Hoffmann R. Designer antibacterial peptides kill fluoroquinolone-resistant clinical isolates. J Med Chem 48 (2005) 5349-5359
8. Otvos Jr. L., Snyder C., Condie B., Bulet P., and Wade J.D. Chimeric antimicrobial peptides exhibit multiple modes of action. Int J Pept Res Ther 11 (2005) 29-42
9. Otvos Jr. L., de Olivier Inacio V., Wade J.D., and Cudic P. Prior antibacterial peptide-mediated inhibition of protein folding in bacteria mutes resistance enzymes. Antimicrob Agents Chemother 50 (2006) 3146-3149
10. Kragol G., Lovas S., Varadi G., Condie B.A., Hoffmann R., and Otvos Jr. L. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry 40 (2001) 3016-3026
11. Noto P.B., Abbadessa G., Cassone M., Mateo G.D., Agelan A., Wade J.D., et al. Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. Protein Sci 17 (2008) 1249-1255
12. Kim J.M., Ha J.R., Oh S.W., Kim H.G., Lee J.M., Lee D.G., et al. CW-270033, a novel pyrrolidinyl-thio carbapenem, has potent antimicrobial activity in vitro and in vivo. Biol Pharm Bull 30 (2007) 575-579
13. Klootwijk W., Sleddens-Linkels E., de Boer R., Jansen C.A., Autar R., de Herder W.W., et al. Renal clearance of the thyrotropin-releasing hormone-like peptide pyroglutamyl-glutamyl-prolineamide in humans. J Clin Endocrinol Metab 82 (1997) 3068-3073
14. Sakamoto H., Hatano K., HigashiY, Mine Y., Nakamoto S., Tawara S., et al. Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin. J Antibiot (Tokyo) 46 (1993) 120-130
15. Fields G.B., and Noble R.L. Solid-phase peptide synthesis using 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35 (1990) 161-214
16. Amsterdam D. Susceptibility testing of antimicrobials in liquid media. In: Loman V. (Ed). Antibiotics in laboratory medicine (1996), Williams and Wilkins, Philadelphia, PA 52-111
17. Otvos Jr. L., O I., Rogers M.E., Consolvo P.J., Condie B.A., Lovas S., et al. Interaction between heat shock proteins and antimicrobial peptides. Biochemistry 39 (2000) 14150-14159
18. Kragol G., Hoffmann R., Chattergoon M.A., Lovas S., Cudic M., Bulet P., et al. Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrhocoricin. Eur J Biochem 269 (2002) 4226-4237
19. Cassone M., Vogiatzi P., La Montagna R., De Olivier Inacio V., Cudic P., Wade J.D., et al. Scope and limitations of the designer proline-rich antibacterial peptide dimer, A3-APO, alone or in synergy with conventional antibiotics. Peptides 29 (2008) 1878-1886
20. Otvos Jr. L. Antibacterial peptides and proteins with multiple cellular targets. J Pept Sci 11 (2005) 697-706
21. Cassone M., Frith N., Vogiatzi P., Wade J.D., and Otvos Jr. L. Induced resistance to the designer proline-rich antimicrobial peptide A3-APO does not involve changes in the intracellular target DnaK. Int J Pept Res Ther 15 (2009) 121-128
22. Rozgonyi F., Szabo D., Kocsis B., Ostorházi E., Abbadessa G., Cassone M., et al. The antibacterial effect of a proline-rich antibacterial peptide A3-APO. Curr Med Chem 16 (2009) 3996-4002
23. Fumarola D., Marcuccio L., Fransvea P., Pasquetto N., Miragliotta G., and Brienza A. Attempted protection against experimental endotoxic shock. G Batteriol Virol Immunol 68 (1975) 224-230 [in Italian]
24. Byl B.P., Clevenbergh A., Kentos F., Jacobs F., Marchant A., Vincent J.L., et al. Ceftazidime- and imipenem-induced endotoxin release during treatment of Gram-negative infections. Eur J Clin Microbiol Infect Dis 20 (2001) 804-807
25. Máthé A., Komka K., Forczig M., Szabó D., Anderlik P., and Rozgonyi F. The effect of different doses of cisplatin on the pharmacokinetic parameters of cefepime in mice. Lab Anim 40 (2006) 296-300
26. Edwards J.R., Williams S., and Nairn K. Therapeutic activity of meropenem in experimental infections. J Antimicrob Chemother 24 Suppl. A (1989) 279-285
27. Cudic M., Lockatell C.V., Johnson D.E., and Otvos Jr. L. In vitro and in vivo activity of a designed antibacterial peptide analog against uropathogens. Peptides 24 (2003) 807-820